We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 2.33% | 6.60 | 6.02 | 7.18 | - | 247,694 | 16:35:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.74 | 12.99M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/3/2020 16:42 | Dont get too complacent here....call me old fashioned..I sold half my holding earlier and made 2.7k....hope we all do really well but be careful....rampers galore around!! Stay safe. | goofrob | |
23/3/2020 16:35 | Me2 at 51p That's 3 top ups for me today | bmnsa | |
23/3/2020 16:29 | just had a few more before close, couldn't resist | thwarnts | |
23/3/2020 16:28 | Link are dumping big time like rats | iamgreat1 | |
23/3/2020 16:25 | The good old gap. The gamble was would they fill it or would you be left buying higher thinking they would will it when they decided not to. If the mms want stock they will keep squeezing you out until it is filled. Same happened on the previous spike as the free float is minuscule. | tidy 2 | |
23/3/2020 16:13 | Gap filled...strong close coming up. | likya123 | |
23/3/2020 16:12 | Never thought people would be getting a second chance to buy here! | dave444 | |
23/3/2020 16:10 | Just a case of filling the gap which is better if it is necessary. | tidy 2 | |
23/3/2020 15:49 | That is bound to happen. You always get a second wave in a pandemic. | nobbygnome | |
23/3/2020 15:30 | Cytokines are crucial for activating cells and drivig the immune response. Beta interferon is itself one of the many cytokines. | nobbygnome | |
23/3/2020 15:30 | Not antibodies but cytokines (I think) produced by the cells activated by the beta interferon. It takes a couple of weeks to generate antibodies. | nobbygnome | |
23/3/2020 15:26 | CEO states after 1 dose of SNG001 patients were showing signs of antibodies produced by the time their second dose was ready to be administered the following day. Excellent. | tidy 2 | |
23/3/2020 15:16 | Gilead's market cap has increased by about $10 billion since announcing their drug Remdesivir may be helpful. So don't feel too sorry for them. | pdt | |
23/3/2020 15:16 | Possibly due to their Sunday announcement on halting emergency supplies? Many punters think these experimental drugs can be ramped up to a global scale within a couple of weeks... | briannewby | |
23/3/2020 15:12 | Hi Brian, I know it is a bit of a dinosaur company but Gilead down about 2.3% at the moment. Crazy, IMO. | freedosh | |
23/3/2020 15:02 | Not sure if already posted so apologies if it has -https://www.europea | tickboo | |
23/3/2020 14:55 | Freedosh - I see Remdesivir (Gilead) is one of the treatment modalities announced today in the 3200 patient European trial which also starts today. Being an open trial should get initial analysis of efficacy in a couple of weeks. | briannewby | |
23/3/2020 14:37 | Tidy Spot on. | jev1 | |
23/3/2020 14:26 | Exactly. He knows it works. It sparks your natural virus defence system even if you dont have a virus that is how effective it is and how they know it works. | tidy 2 | |
23/3/2020 14:16 | Nobby - This is what I posted on 11th November and if you look at the article the research shows it was of no use in infected cells; Interesting article published in the American Journal of Respiratory and Critical Care Medicine; Dynamics of IFN-β Responses During Respiratory Viral Infection: Insights for Therapeutic Strategies the abstract concludes; "CONCLUSIONS: In vitro modelling of IFN-β dynamics highlights the potential for intermittent prophylactic doses of exogenous IFN-β to modulate viral infection. This provides important insights to aid the future design of clinical trials of IFN-β in asthma and COPD" The authors are from University Hospital Southampton and Astrazeneca, Sweden. And on a seperate note thanks for your work on this thread Nobby, we all appreciate it! | pdt | |
23/3/2020 14:12 | when a patient inhales the stuff you would know within a couple of hours if it is having an impact - similar to getting a nebuliser dose when you are an asthmatic. So I don't see why the Gov will wait ages to see the complete results - this will be used quick and rolled out if it works | asif12 | |
23/3/2020 14:09 | PDT That is what I understood it protects the healthy part of the lung. Of paramount importance so afterwards they are not totally disabled by it if they recover. | hazl | |
23/3/2020 14:09 | In addition to the indirect antiviral activity of INF-beta it also promotes anti-inflammatory cytokines that should help protect the lung and reduce immediate and late toxicity including fibrosis. The later is the reason that I am invested here. FARN will achieve the same but by a parenteral route. Anti-IL6 and IL6R MoAbs seem a little neglected but will likely have the best lung (ARDS) protective properties e.g. Chugai,Roche, Tiziana (TILS). Best current prospect for an effective drug is from Gilead and vaccine from Moderna. All IMO Declaration; I hold NCYT,SGN and TILS. | freedosh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions